AcelRx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Talphera

14/11/2022 22:03

* AcelRx Pharmaceuticals Inc  ACRX.OQ  reported a quarterly
adjusted loss of 94 cents​​ per share for the quarter ended in
September. The mean expectation of two analysts for the quarter
was for a loss of $1.20 per share.
    * Revenue fell 72.8% to $507.00 thousand from a year ago;
analysts
expected $625.00 thousand. 
    * AcelRx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 94 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * AcelRx Pharmaceuticals Inc shares had fallen by 50.7% this
quarter and lost 81.6% so far this year.
    * The company reported a quarterly loss of $6.94 million.
    * Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $80.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.20          -0.94          Beat
 Jun. 30 2022      -1.50          -1.20          Beat
 Mar. 31 2022      -1.20          -1.20          Met
 Dec. 31 2021      -1.40          -1.20          Beat